SCHEMBL2922964

SCHEMBL2922964

CS(=O)(=O)c1ccc2c(C(=O)O)c[nH]c(=O)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.54
▸ LMNA P02545 1/20 0.50
▸ HSD17B10 Q99714 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HRH1 P35367 4/20 0.42
▸ CCR3 P51677 4/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ POLB P06746 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SPR P35270 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2916325 0.94 KDM4E (0.54) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL2922360 0.86 KDM4E (0.56) KDM4EHSD17B10HPGDGAAMAPT
SCHEMBL2920920 0.85 KDM4E (0.54) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL2916302 0.85 KDM4E (0.54) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL2913348 0.84 KDM4E (0.50) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL2923292 0.84 KDM4E (0.50) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL23612225 0.81 GAA (0.58) KDM4ELMNAHSD17B10HPGDGAA
SCHEMBL2920694 0.81 LMNA (0.53) LMNAHSD17B10HPGDGAAMAPT
SCHEMBL11330088 0.80 LMNA (0.59) KDM4ELMNAHSD17B10HPGD
SCHEMBL2914957 0.80 NR4A2 (0.48) MAPTHRH1CCR3KCNH2SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 — — EP disclosed
EP-1478624-B1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-08 — — EP disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
CN-100564358-C The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines ASTRAZENECA AB (SE) 2009-12-02 — — CN disclosed
CN-100352807-C substituted piperidine compounds ASTRAZENECA AB (SE) 2007-12-05 — — CN disclosed
CN-1907968-A Method for making 4-(3,4-dichlorophenoxy)piperidine ASTRAZENECA AB (SE) 2007-02-07 — — CN disclosed
CN-1633414-A Compound (I) ASTRAZENECA AB (SE) 2005-06-29 — — CN disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 KDM4E 1685/4885LMNA 4760/4885HSD17B10 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback